Download PDF
Int J Sports Med 2018; 39(10): 743-748
DOI: 10.1055/a-0633-8892
Physiology & Biochemistry
© Georg Thieme Verlag KG Stuttgart · New York

Eccentric Overload Muscle Damage is Attenuated By a Novel Angiotensin- (1-7) Treatment

Lenice Kappes Becker
3   Sports Department, School of Physical Education, Physiotherapy, and Occupational Therapy (EEFFTO), Federal University of Minas Gerais, Brazil
1   National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil
,
Nádia Totou
2   Sport Center, Federal University of Ouro Preto, Ouro Preto, Brazil
,
Samara Moura
2   Sport Center, Federal University of Ouro Preto, Ouro Preto, Brazil
,
Lucas Kangussu
3   Sports Department, School of Physical Education, Physiotherapy, and Occupational Therapy (EEFFTO), Federal University of Minas Gerais, Brazil
,
Ruben Dario Sinisterra Millán
1   National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil
4   Department of Chemistry, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
,
Maria Jose Campagnole-Santos
1   National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil
,
Daniel Coelho
2   Sport Center, Federal University of Ouro Preto, Ouro Preto, Brazil
,
Daisy Motta-Santos
1   National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil
3   Sports Department, School of Physical Education, Physiotherapy, and Occupational Therapy (EEFFTO), Federal University of Minas Gerais, Brazil
,
Robson Augusto Souza Santos
1   National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais, Brazil
› Author Affiliations
Further Information

Publication History



accepted 20 April 2018

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The development of new strategies to attenuate exercise-induced muscle damage may be helpful for training regimens. The aim of this study was to determine whether a oral formulation of angiotensin Ang-(1-7)[HPβCD/Ang-(1-7)] is effective to reduce pain, and muscle damage markers after eccentric-overload exercise. HPβCD (Placebo) and HPβCD/Ang-(1-7) (Ang-(1-7) group were treated for 7 days (one capsule/day). The pain was measured by visual analogue scale, maximal strength (MS) using force platform. Blood samples were collected for cytokines and creatine kinase (CK) analysis. The Ang-(1-7)-treated group reported less pain immediately (3.46±0.64 vs. placebo 3.80±0.77 cm) and 24 h after exercise (3.07±0.71 vs. 3.73±0.58 cm placebo) and higher MS at 24 h (24±12 N) and 48 h (30±15 N) vs. placebo (-8±9 N and -10±9 N). The CK for Ang-(1-7) (0.5±0.1 and 0.9±0.2 U/L) were lower at 48 and 72 h vs. placebo (fold changes of 1.7±0.5 and 1.5±0.3 U/L). The TNF-α level was lower in the treated group post-exercise (38±2.5 pg/ml) vs. placebo (45±2.9 pg/ml) but no significant changes were observed for IL-6 and IL-10. Our data indicate that treatment with Ang-(1-7) may attenuate pain, some of the muscle damage markers and improves performance following eccentric exercise.

Key words

physical performance - angiotensin-(1-7) - muscular damage
 

  • References

  • 1 Acuna MJ, Pessina P, Olguin H, Cabrera D, Vio CP, Bader M, Munoz-Canoves P, Santos RA, Cabello-Verrugio C, Brandan E. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-beta signalling. Hum Mol Genet 2014; 23: 1237-1249
    CrossrefPubMedGoogle Scholar
  • 2 Baird MF, Graham SM, Baker JS, Bickerstaff GF. Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. J Nutr Metab 2012; 2012: 960363
    Google Scholar
  • 3 Baldwin Lanier A. Use of nonsteroidal anti-inflammatory drugs following exercise-induced muscle injury. Sports Med 2003; 33: 177-185
    CrossrefPubMedGoogle Scholar
  • 4 Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-Angiotensin system: An old player with novel functions in skeletal muscle. Med Res Rev 2015; 35: 437-463
    CrossrefPubMedGoogle Scholar
  • 5 Cheung K, Hume P, Maxwell L. Delayed onset muscle soreness: Treatment strategies and performance factors. Sports Med 2003; 33: 145-164
    CrossrefPubMedGoogle Scholar
  • 6 Cisternas F, Morales MG, Meneses C, Simon F, Brandan E, Abrigo J, Vazquez Y, Cabello-Verrugio C. Angiotensin-(1-7) decreases skeletal muscle atrophy induced by angiotensin II through a Mas receptor-dependent mechanism. Clin Sci (Lond) 2015; 128: 307-319
    CrossrefPubMedGoogle Scholar
  • 7 Clarkson PM, Nosaka K, Braun B. Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc 1992; 24: 512-520
    PubMedGoogle Scholar
  • 8 Costa AC, Becker LK, Moraes ER, Romero TR, Guzzo L, Santos RA, Duarte ID. Angiotensin-(1-7) induces peripheral antinociception through mas receptor activation in an opioid-independent pathway. Pharmacology 2012; 89: 137-144
    CrossrefPubMedGoogle Scholar
  • 9 Forte BL, Slosky LM, Zhang H, Arnold MR, Staatz WD, Hay M, Largent-Milnes TM, Vanderah TW. Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. Pain 2016; 157: 2709-2721
    CrossrefPubMedGoogle Scholar
  • 10 Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD, Santos RA. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo) 2011; 66: 837-841
    CrossrefPubMedGoogle Scholar
  • 11 Fraga-Silva RA, Costa-Fraga FP, Savergnini SQ, De Sousa FB, Montecucco F, da Silva D, Sinisterra RD, Mach F, Stergiopulos N, da Silva RF, Santos RA. An oral formulation of Angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med 2013; 10: 2430-2442
    CrossrefPubMedGoogle Scholar
  • 12 Hamada K, Vannier E, Sacheck JM, Witsell AL, Roubenoff R. Senescence of human skeletal muscle impairs the local inflammatory cytokine response to acute eccentric exercise. FASEB J 2005; 19: 264-266
    CrossrefPubMedGoogle Scholar
  • 13 Harriss DJ, Macsween A, Atkinson G. Standards for ethics in sport and exercise science research: 2018 update. Int J Sports Med 2017; 38: 1126-1131
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lombardi G, Ziemann E, Banfi G. Whole-body cryotherapy in athletes: From therapy to stimulation. An updated review of the literature. Front Physiol 2017; 8: 258
    CrossrefPubMedGoogle Scholar
  • 15 Lula I, Denadai AL, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, Heine T, Duarte HA, Santos RA, Sinisterra RD. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides 2007; 28: 2199-2210
    CrossrefPubMedGoogle Scholar
  • 16 MacIntyre DL, Reid WD, McKenzie DC. Delayed muscle soreness. The inflammatory response to muscle injury and its clinical implications. Sports Med 1995; 20: 24-40
    CrossrefPubMedGoogle Scholar
  • 17 Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, Melo MB, Nadu AP, Souza LE, Irigoyen MC, Almeida AP, Santos RA. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011; 57: 477-483
    CrossrefPubMedGoogle Scholar
  • 18 Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, Savergnini SQ, Braga VB, Ferreira AJ, Santos RA. Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012; 2012: 795452
    PubMedGoogle Scholar
  • 19 McCollum LT, Gallagher PE, Ann Tallant E. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol 2012; 302: H801-H810
    CrossrefPubMedGoogle Scholar
  • 20 Motta-Santos D, Dos Santos RA, Oliveira M, Qadri F, Poglitsch M, Mosienko V, Kappes Becker L, Campagnole-Santos MJ, Penninger JM, Alenina N, Bader M. Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise. Hypertens Res 2016; 39: 506-512
    CrossrefPubMedGoogle Scholar
  • 21 Oliveira Andrade JM, Paraiso AF, Garcia ZM, Ferreira AV, Sinisterra RD, Sousa FB, Guimaraes AL, de Paula AM, Campagnole-Santos MJ, dos Santos RA, Santos SH. Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides 2014; 55: 158-165
    CrossrefPubMedGoogle Scholar
  • 22 Pachauri P, Garabadu D, Goyal A, Upadhyay PK. Angiotensin (1-7) facilitates cardioprotection of ischemic preconditioning on ischemia-reperfusion-challenged rat heart. Mol Cell Biochem 2017; 430: 99-113
    CrossrefPubMedGoogle Scholar
  • 23 Paschalis V, Koutedakis Y, Jamurtas AZ, Mougios V, Baltzopoulos V. Equal volumes of high and low intensity of eccentric exercise in relation to muscle damage and performance. J Strength Cond Res 2005; 19: 184-188
    PubMedGoogle Scholar
  • 24 Proença JK. Estudo clínico (FASE1) da farmacocinética e tolerabilidade de uma nova formulação oral do peptídeo angiotensina-(1-7) incluído em HP-beta-ciclodextrina em voluntários saudáveis. Universidade Federal de Minas Gerais; 2016
    Google Scholar
  • 25 Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance: 12 years on. Sports Med 2011; 41: 433-448
    CrossrefPubMedGoogle Scholar
  • 26 Romain C, Freitas TT, Martinez-Noguera FJ, Laurent C, Gaillet S, Chung LH, Alcaraz PE, Cases J. Supplementation with a polyphenol-rich extract, TensLess((R)), attenuates delayed onset muscle soreness and improves muscle recovery from damages after eccentric exercise. Phytother Res 2017; 31: 1739-1746
    CrossrefPubMedGoogle Scholar
  • 27 Saka T, Akova B, Yazici Z, Sekir U, Gür H, Ozarda Y. Difference in the magnitude of muscle damage between elbow flexors and knee extensors eccentric exercises. J Sports Sci Med 2009; 8: 107-115
    PubMedGoogle Scholar
  • 28 Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev 2018; 98: 505-553
    CrossrefPubMedGoogle Scholar
  • 29 Sayers SP, Clarkson PM. Short-term immobilization after eccentric exercise. Part II: Creatine kinase and myoglobin. Med Sci Sports Exerc 2003; 35: 762-768
    CrossrefPubMedGoogle Scholar
  • 30 Silva JR, Rumpf MC, Hertzog M, Castagna C, Farooq A, Girard O, Hader K. Acute and residual soccer match-related fatigue: A systematic review and meta-analysis. Sports Med 2018; 48: 539-583
    CrossrefPubMedGoogle Scholar
  • 31 Townsend JR, Fragala MS, Jajtner AR, Gonzalez AM, Wells AJ, Mangine GT, Robinson EHt, McCormack WP, Beyer KS, Pruna GJ, Boone CH, Scanlon TM, Bohner JD, Stout JR, Hoffman JR. beta-Hydroxy-beta-methylbutyrate (HMB)-free acid attenuates circulating TNF-alpha and TNFR1 expression postresistance exercise. J Appl Physiol (1985) 2013; 115: 1173-1182
    CrossrefPubMedGoogle Scholar
  • 32 Warren GL, Lowe DA, Armstrong RB. Measurement tools used in the study of eccentric contraction-induced injury. Sports Med 1999; 27: 43-59
    CrossrefPubMedGoogle Scholar
  • 33 Zainuddin Z, Newton M, Sacco P, Nosaka K. Effects of massage on delayed-onset muscle soreness, swelling, and recovery of muscle function. J Athl Train 2005; 40: 174-180
    PubMedGoogle Scholar